Case studies: Successful scale-up of upstream viral vector processes using adherent and suspension platforms
Sponsor
Cell and gene therapies have emerged as promising treatments for previously untreatable diseases, and viral vectors are currently the preferred gene-delivery vehicle for most cell and gene therapies. For this reason, safe, robust, and cost-effective manufacturing processes are necessary to support the demands of the patient population. However, complexity around developing and scaling viral vector processes to commercial manufacturing scale, and the lack of standardized approaches, remain as challenges that can impact therapy development timelines and productivity. Selection of the appropriate production platform plays a key role in the successful implementation of a process that meets the commercialization timelines and manufacturing costs.
During this webinar, we will share two case studies that demonstrate successful scale-up for viral vectors, leveraging Pall’s platform, process expertise, and platform knowledge to help accelerate the development timelines.
- The first details the process development and scale-up for a Helper-Dependent-Adenovirus (HDAd) using adherent culture and the iCELLis® bioreactor platform
- Secondly, Andelyn Biosciences, a contract manufacturing organization, presents on the development of a highly productive Adeno Associated Virus (AAV) suspension process and how they worked with Pall’s Process Development Services to scale-up to 500 L and 1000 L scale, using the Allegro™ STR bioreactor platform
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
